ArticleCancer medicine2023

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non-small cell lung cancer patients.

Masahiro Torasawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.